15-May-2026
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)
TipRanks (Wed, 13-May 8:27 AM ET)
Newsfile (Tue, 12-May 2:16 PM ET)
Globe Newswire (Tue, 12-May 9:30 AM ET)
PRNewswire (Mon, 11-May 10:10 PM ET)
Disc Medicine to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 11-May 8:30 AM ET)
Newsfile (Tue, 5-May 5:26 PM ET)
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Tue, 5-May 8:30 AM ET)
Newsfile (Sun, 3-May 9:27 PM ET)
PRNewswire (Thu, 30-Apr 10:40 PM ET)
Newsfile (Wed, 29-Apr 5:32 PM ET)
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Disc Medicine trades on the NASDAQ stock market under the symbol IRON.
As of May 15, 2026, IRON stock price declined to $66.86 with 753,377 million shares trading.
IRON has a beta of 1.12, meaning it tends to be more sensitive to market movements. IRON has a correlation of 0.07 to the broad based SPY ETF.
IRON has a market cap of $2.55 billion. This is considered a Mid Cap stock.
Last quarter Disc Medicine reported $0 in Revenue and -$1.65 earnings per share. This fell short of revenue expectation by $-50,000 and exceeded earnings estimates by $.04.
In the last 3 years, IRON traded as high as $99.50 and as low as $25.60.
The top ETF exchange traded funds that IRON belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
IRON has outperformed the market in the last year with a return of +42.0%, while the SPY ETF gained +26.4%. In the last 3 month period, IRON beat the market returning +19.5%, while SPY returned +8.7%. However, in the most recent 2 weeks IRON has underperformed the stock market by returning -0.1%, while SPY returned +2.6%.
IRON support price is $67.69 and resistance is $71.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRON shares will trade within this expected range on the day.